Grimes & Company, Inc. Outlook Therapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.22 Billion
- Q1 2024
Shares
1 transactions
Others Institutions Holding OTLK
# of Institutions
6Shares Held
66.9KCall Options Held
0Put Options Held
0-
Prospera Financial Services Inc30.5KShares$232,1050.0% of portfolio
-
Endurance Wealth Management, Inc.20KShares$152,2000.0% of portfolio
-
Urban Wealth Management, LLC7.47KShares$56,8690.03% of portfolio
-
American Portfolios Advisors Holbrook, NY4KShares$30,4400.0% of portfolio
-
Armstrong Advisory Group, Inc Needham, MA3.58KShares$27,2430.0% of portfolio
About Outlook Therapeutics, Inc.
- Ticker OTLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 226,144,992
- Market Cap $1.72B
- Description
- Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...